Rei Wake

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2035430/publications.pdf

Version: 2024-02-01

687363 713466 28 443 13 21 h-index citations g-index papers 28 28 28 669 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Urinary biopyrrins and free immunoglobin light chains are biomarker candidates for screening atâ€risk mental state in adolescents. Microbial Biotechnology, 2022, 16, 272-280.	1.7	1
2	Contribution of "Genuine Microglia―to Alzheimer's Disease Pathology. Frontiers in Aging Neuroscience, 2022, 14, 815307.	3.4	0
3	Normalizing hyperactivity of the Gunn rat with bilirubin-induced neurological disorders via ketanserin. Pediatric Research, 2021, , .	2.3	2
4	Studies Support the Use of Suvorexant for the Prevention of Delirium. Journal of Clinical Psychiatry, 2021, 82, .	2.2	0
5	Efficacy and safety of Ninjin'yoeito (NYT) in treatment-resistant schizophrenia: Open-Label Study. Asian Journal of Psychiatry, 2021, 60, 102662.	2.0	0
6	The effectiveness of electroconvulsive therapy for psychiatric symptoms and cognitive fluctuations similar to dementia with Lewy bodies: a case report. Psychogeriatrics, 2020, 20, 229-231.	1.2	4
7	Low Serum Levels of Fibroblast Growth Factor 2 in Gunn Rats: A Hyperbilirubinemia Animal Model of Schizophrenic Symptoms. CNS and Neurological Disorders - Drug Targets, 2020, 19, 503-508.	1.4	1
8	Real-World Preventive Effects of Suvorexant in Intensive Care Delirium. Journal of Clinical Psychiatry, 2020, 81, .	2.2	8
9	The Possible Causal Link of Periodontitis to Neuropsychiatric Disorders: More Than Psychosocial Mechanisms. International Journal of Molecular Sciences, 2019, 20, 3723.	4.1	55
10	Parvalbumin-positive GABAergic interneurons deficit in the hippocampus in Gunn rats: A possible hyperbilirubinemia-induced animal model of schizophrenia. Heliyon, 2019, 5, e02037.	3.2	5
11	Electroconvulsive shock restores the decreased coverage of brain blood vessels by astrocytic endfeet and ameliorates depressive-like behavior. Journal of Affective Disorders, 2019, 257, 331-339.	4.1	15
12	Gunn rats with glial activation in the hippocampus show prolonged immobility time in the forced swimming test and tail suspension test. Brain and Behavior, 2018, 8, e01028.	2.2	26
13	Cognitive Behavioral Therapy for Insomnia as Adjunctive Therapy to Antipsychotics in Schizophrenia: A Case Report. Frontiers in Psychiatry, 2018, 9, 260.	2.6	2
14	Implications of Systemic Inflammation and Periodontitis for Major Depression. Frontiers in Neuroscience, 2018, 12, 483.	2.8	52
15	Remission of Psychosis in Treatment-Resistant Schizophrenia following Bone Marrow Transplantation: A Case Report. Frontiers in Psychiatry, 2017, 8, 174.	2.6	28
16	Electroconvulsive shock attenuated microgliosis and astrogliosis in the hippocampus and ameliorated schizophrenia-like behavior of Gunn rat. Journal of Neuroinflammation, 2016, 13, 230.	7.2	32
17	Ramelteon as adjunctive therapy for delirium referred to a consultationâ€iaison psychiatry service: a retrospective analysis. International Journal of Geriatric Psychiatry, 2015, 30, 994-995.	2.7	9
18	Analysis of oxidative stress expressed by urinary level of biopyrrins and 8â€hydroxydeoxyguanosine in patients with chronic schizophrenia. Psychiatry and Clinical Neurosciences, 2015, 69, 693-698.	1.8	17

#	Article	IF	CITATION
19	Efficacy and Safety of Yokukansan in Treatment-Resistant Schizophrenia: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial. Evidence-based Complementary and Alternative Medicine, 2015, 2015, 1-11.	1.2	7
20	Can inhibition of microglial activation cure schizophrenia?. Schizophrenia Research, 2015, 168, 583-584.	2.0	2
21	Minocycline improves recognition memory and attenuates microglial activation in Gunn rat: A possible hyperbilirubinemia-induced animal model of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2014, 50, 184-190.	4.8	31
22	Yokukansan promotes hippocampal neurogenesis associated with the suppression of activated microglia in Gunn rat. Journal of Neuroinflammation, 2013, 10, 145.	7.2	36
23	Yokukansan (TJ-54) for Irritability Associated with Pervasive Developmental Disorder in Children and Adolescents: A 12-Week Prospective, Open-Label Study. Journal of Child and Adolescent Psychopharmacology, 2013, 23, 329-336.	1.3	9
24	Yokukansan (TJ-54) for treatment of very-late-onset schizophrenia-like psychosis: An open-label study. Phytomedicine, 2013, 20, 654-658.	5.3	17
25	Glia: An Important Target for Anti-Inflammatory and Antidepressant Activity. Current Drug Targets, 2013, 14, 1322-1328.	2.1	22
26	Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger's disorder: a 12-week prospective, open-label study. BMC Psychiatry, 2012, 12, 215.	2.6	16
27	Yi-Gan San for Treatment of Charles Bonnet Syndrome (Visual Hallucination Due to Vision Loss). Clinical Neuropharmacology, 2011, 34, 24-27.	0.7	16
28	Hyperbilirubinemia-related behavioral and neuropathological changes in rats: A possible schizophrenia animal model. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2009, 33, 581-588.	4.8	30